Principal findings
A total of 225 participants were enrolled, and 222 (98.7%) seen at 3 weeks. The cure rate in the dual-dose group was 96.4% (95% CI: 90.9–99%), higher than 83.9% (95% CI: 75.7–90.2%) in the single-dose group (OR: 5.07, 95% CI:1.61–15.96, 